Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.

Zhen-Duo ShiLin HaoXiao-Xiao HanZhuo-Xun WuKun PangYang DongJia-Xin QinGuang-Yue WangXuan-Ming ZhangTian XiaQing LiangYan ZhaoRui LiShao-Qi ZhangJun-Hao ZhangJian-Gang ChenGong-Cheng WangZhe-Sheng ChenCong-Hui Han

Published in: Molecular cancer (2022)

Our study demonstrated that HNRNPU expression is associated with cisplatin sensitivity in bladder urothelial carcinoma cells. Inhibition of HNRNPU could be a potential therapy for cisplatin-resistant bladder cancer.

Keyphrases

poor prognosis
urinary tract
high grade
risk assessment
binding protein
human health
long non coding rna